

Synthesis of Trifluoroethyl Pyrazolines via Trichloroisocyanuric Acid Promoted Cascade Cyclization/Trifluoromethylation of α,β -Unsaturated Hydrazones

Bingbing Chang, Yingpeng Su, Danfeng Huang, Ke-Hu Wang, Weigang Zhang, Ya Shi, Xinghu Zhang, and Yulai Hu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b00009 • Publication Date (Web): 30 Mar 2018

Downloaded from <http://pubs.acs.org> on March 30, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



Synthesis of Trifluoroethyl Pyrazolines via Trichloroisocyanuric Acid Promoted Cascade Cyclization/Trifluoromethylation of β,γ -Unsaturated Hydrazones

Bingbing Chang,[†] Yingpeng Su,[†] Danfeng Huang,[†] Ke-Hu Wang,[†] Weigang Zhang,[†] Ya Shi,[†] Xinghu


Zhang,[†] Yulai Hu*^{†‡}

[†]College of Chemistry and Chemical Engineering, Northwest Normal University, 967 Anning East Road, Lanzhou 730070, China

[‡]State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, China

E-mail: huy1@nwnu.edu.cn.

Abstract



A novel and efficient protocol for the construction of trifluoroethyl pyrazolines has been developed by cascade cyclization/trifluoromethylation reaction of β,γ -unsaturated hydrazones. This strategy uses cheap and commercially available trichloroisocyanuric acid as promoter and TMSCF_3 as the trifluoromethylating reagent, which make trifluoromethylating process much cheaper. A wide range of substrates can be applied in this process to afford the trifluoroethyl pyrazolines in good yield.

INTRODUCTION

Trifluoromethyl group is the most prevalent fluorine-containing group appeared in pharmaceuticals,¹ agrochemicals² and material science³ owing to its unique properties such as

significantly enhanced lipophilicity, metabolic stability, and bioactivities comparing to their parent compounds. Thus, strategies to introduce CF₃ group into organic compounds have been greatly investigated in recent years.^{1d,4} Among existed methods, trifluoromethylation reagents such as Togni,^{4a,5} Umemoto,⁶ Ruppert-Prakash reagent (Me₃SiCF₃),^{4b,4g,7} Langlois/Baran reagent (CF₃SO₂M; M = Na, Zn)⁸ and others provide direct and effective ways to introduce CF₃ group into organic compounds. Due to its advantages such as easy handling and storage, low cost and commercially availability in large quantity, Me₃SiCF₃ has been widely applied in trifluoromethylation process. Except its traditional nucleophilic trifluoromethylation process, the radical trifluoromethylation protocol with Me₃SiCF₃ is another interesting way.⁹ For instance, combinations of Me₃SiCF₃ with PhI(OAc)₂, silver or copper salts have been demonstrated as an effective way for the formation of C-CF₃ bond.^{9a,9b,9d} Despite such achievements, a more cheap and practical method for the synthesis of trifluoromethyl organic compound is still highly desirable.

Trichloroisocyanuric acid (TCCA) has been produced on large scale in 100000 t/year and used for many purposes, such as disinfecting swimming pools, nonshrinking treatment of wool, cleaning and sterilizing bathrooms, laundry bleach and other purpose.¹⁰ In organic synthesis, TCCA has been mainly applied as chlorination and oxidation reagents.¹¹ In our research works on fluorine chemistry, we find that TCCA can successfully induce the trifluoromethylation reaction of allylic oximes by using Me₃SiCF₃ as trifluoromethyl source.¹² Obviously, low cost and easy availability of TCCA and Me₃SiCF₃ make it a very interesting trifluoromethylation process.





Figure 1. Examples of biologically active CF₃-containing pyrazolines.

On the other hand, pyrazolines play an important role in drug discovery and organic synthesis.¹³ As for their fluorine derivatives, CF₃-containing pyrazolines have been proven to possess remarkable bioactivities (Figure 1).¹⁴ However, efficient methods for the synthesis of CF₃-containing pyrazoline derivatives have been scarce in literature.¹⁵ [3+2] Cycloadditions of CF₃CH₂N₂ with electron-deficient olefins are reported to give CF₃-substituted pyrazolines.^{15a-c} Cyclocondensations of hydrazines with trifluoromethylated α,β -unsaturated ketones or 1,3-dicarbonyl compounds are other ways to obtain CF₃-substituted pyrazolines.^{15d-e} Recently, a cascade photocatalytic radical trifluoromethylation/cyclization of β,γ -unsaturated hydrazones was reported to afford trifluoroethyl pyrazolines by using Umemoto's reagent as trifluoromethyl source in the presence of Ru(bpy)₃(PF₆)₂ as photocatalyst (Scheme 1, a).^{15f} Herein, we would like to report that TCCA promoted cascade cyclization/trifluoromethylation of β,γ -unsaturated hydrazones by using Me₃SiCF₃ as trifluoromethyl source to give trifluoroethyl pyrazolines in good yields (Scheme 1, b).


Scheme 1. Synthesis of Trifluoroethyl Pyrazolines.

a) Previous work^{15f}



R¹ = Aryl, Alkyl; R² = Aryl; R³ = Ts, Aryl

b) This work



R¹ = Aryl, Alkyl; R² = Ts, Boc, Cbz, Acyl

RESULTS AND DISCUSSION

The initial investigation commenced with the reaction of *N-p*-toluenesulfonyl- β,γ -unsaturated hydrazones **1a** between TMSCF₃ and TCCA in the presence of CsF and CuCl in acetonitrile (CH₃CN) under argon atmosphere at room temperature. After the reaction finished, the desired trifluoroethyl pyrazoline **5a** was formed in 55% yield along with chlorinated by-product **6a** in 23% yield (Table 1, entry 1). As reported in literature, metal salts usually have great influence on the trifluoromethylation by using TMSCF₃ as trifluoromethyl reagent due to the formation of trifluoromethyl organometallic reagents (MCF₃).¹⁶ Thus, different metal salts were firstly examined in order to improve the selectivity for desired trifluoromethylated product **5a**. When CuCN was used, the reaction did not occur, and only starting material hydrazones **1a** was recovered in 86% yield (Table 1, entry 2). If Cu(OAc)₂, CuCl₂ or ZnCl₂ was applied in the reaction, there were no trifluoromethylated product **5a** formed, but only the chlorinated product **6a** was produced in moderate yield (Table 1, entries 3–5). Silver acetate could only give the product **5a** without the formation of by-product **6a**, but the yield of **5a** was low (Table 1, entry 6). However, the yield of **5a** was not elevated when the amount of TCCA was further increased (Table 1, entry 7). Finally, when copper(I) acetate was used in the reaction, the yield of **5a** could be improved to 75% meanwhile the starting material **1a** was recovered in 13% and trace amount of by-product **6a** could be seen on TLC (Table 1, entry 8). Afterwards, the amount of TCCA was examined to improve the yield of trifluoromethylated product **5a**. It was found that the amount of TCCA also have some influence on the reaction. When its amount was increased from 0.5 equiv to 0.67 equiv, the yield of **5a** went up to 83%, meanwhile the starting material **1a** disappeared and trace amount of by-product **6a** could be seen on TLC (Table 1, entries 8 and 9). However, further increasing of the TCCA amount to 0.84 equiv led to the decreasing of yield of **5a** down to 15%, and the yield of by-product **6a** went up to 56% at the same time (Table 1, entry 10). Next, other additives such as *N*-Cl-phthalimide,

1 *N*-Chlorosuccinimide (NCS), *N*-Bromosuccinimide (NBS) and *N*-Iodosuccinimide (NIS) were tested
 2
 3 for the reaction, but the yield and selectivity for **5a** were not improved (Table 1, entries 11-14).
 4
 5 Finally, it was found both of copper(I) acetate and TCCA were crucial in the reaction to obtain the
 6
 7 desired product **5a**. For instance, only chlorinated product **6a** was obtained if there was no copper(I)
 8
 9 acetate in the reaction (Table 1, entry 15), and the reaction could not occur neither without TCCA
 10
 11 acetate in the reaction (Table 1, entry 15), and the reaction could not occur neither without TCCA
 12
 13 (Table 1, entry 16). Therefore, the optimized reaction conditions were found to be the use of **1a**,
 14
 15 CuOAc, CsF, TMSCF₃ and TCCA in a molar ratio of 1:3.5:4.2:4.2:0.67 in MeCN at room
 16
 17 temperature under argon atmosphere.

21 **Table 1 Optimization of Reaction Conditions^a**

22
 23
 24
 25
 26
 27
 28
 29

30
 31
 32
 33

entry	metal salt 2	additive (equiv)	time	yield (%)	
				5a	6a
1	CuCl	TCCA (0.5)	0.5 h	55	23
2	CuCN	TCCA (0.5)	4 h	–	–
3	Cu(OAc) ₂	TCCA (0.5)	5 h	–	58
4	CuCl ₂	TCCA (0.5)	1.5 h	–	78
5	ZnCl ₂	TCCA (0.5)	1.5 h	–	63
6	AgOAc	TCCA (0.5)	0.5 h	35	–
7	AgOAc	TCCA (0.67)	20 min	33	–
8	CuOAc	TCCA (0.5)	4 h	75	trace
9	CuOAc	TCCA (0.67)	1.5 h	83	trace
10	CuOAc	TCCA (0.84)	15 min	15	56
11	CuOAc	<i>N</i> -Cl-phthalimide (2.0)	4 h	14	24
12	CuOAc	NCS (2.0)	0.5 h	54	23
13	CuOAc	NIS (2.0)	0.5 h	37	(44) ^b
14	CuOAc	NBS (2.0)	0.5 h	32	(53) ^c

34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60


15	–	TCCA (0.67)	15 min	–	46
16	CuOAc	–	4 h	–	–

^a Unless otherwise noted, the reactions were performed with **1a** (0.3 mmol), additive (0.15-0.6 mmol, 0.5-2.0 equiv), **2** (1.1 mmol, 3.5 equiv), **3** (1.3 mmol, 4.2 equiv), and **4** (1.3 mmol, 4.2 equiv) in 6 mL CH₃CN at room temperature. ^b Yield of 5-(iodomethyl)-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (**6b**). ^c Yield of 5-(bromomethyl)-3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazole (**6c**).

With the optimized reaction conditions in hand, the substrate scope was then investigated. The β,γ -unsaturated hydrazones derived from homoallylic ketones **1** were examined firstly. As shown in Table 2, both of aromatic and aliphatic β,γ -unsaturated hydrazones **1** could produce the corresponding products **5** in good yields. As for the aromatic ketone-derived β,γ -unsaturated hydrazones, electronic properties of substituents on the phenyl rings had little effect on the yields of the products. The β,γ -unsaturated hydrazones with both of electron-donating and electron-withdrawing groups on phenyl rings could afford the products in reasonable to good yields (Table 2, **5a–5j**). However, if the substituents on the phenyl rings were the same, the *ortho*-substituted ones gave the product in lowest yields (Table 2, **5e–5g**). Heterocyclic β,γ -unsaturated hydrazones such as 2-thiophenehydrazone and Boc-protected 3-indolehydrazone were also suitable for this reaction to give the desired product **5k** and **5l** in 47% and 75% yields, respectively. In addition, this protocol could be further applied successfully to a range of linear and branched aliphatic β,γ -unsaturated hydrazones **1m–1p**; and the desired products **5m–5p** were obtained in moderate to high yields (Table 2, **5m–5p**).

Table 2. Scope of β,γ -Unsaturated Hydrazones^a





32
33
34
35
36
37


^aAll reactions were carried out using 0.3 mmol of **1a**, 0.2 mmol of TCCA (0.67 equiv), 1.1 mmol of CuOAc (3.5 equiv), 1.3 mmol of TMSCF₃ (4.2 equiv), 1.3 mmol of CsF (4.2 equiv), and 4 mL of CH₃CN.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In order to examine the generality of the reaction further, the hydrazones with other *N*-protecting groups (R²) such as benzyloxycarbonyl (Cbz), methyl carbonate, *tert*-butoxycarbonyl (Boc) and acyl groups had been investigated (Table 3). It was indicated that the Cbz, carbonate and Boc groups were compatible in the reactions to allow the corresponding products formed in good yields. However, when aliphatic acyl groups such as acetyl and isobutyryl groups were used, the yields of the products were low. For instance, the products **5ar** and **5as** were obtained in only 27% and 34% yields (Table 3, **5ar** and **5as**).

The products obtained in above reaction could be further transformed into pyrazoles. For instance, when compound **5a** was refluxed in methanol in the presence of sodium hydroxide, pyrazole **7** could be produced in 94% yield. Boc-protected compound **5an** could also be transformed into pyrazole **7** in the presence of CuCl₂ under reflux in ethanol (Scheme 2).


Scheme 2. Transformation of the Products




To consider the reaction mechanism, some control experiments were carried out (Scheme 3). Firstly, chlorinated product **6a** obtained at the beginning of this work was used as substrate to carry out the reaction under the standard reaction conditions, but there was no trifluoromethylated product **5a** formed, and **6a** was recovered in 94% yield (Scheme 3, a). This result indicated that desired product **5a** was not produced from the **6a**. Next, TEMPO was added into the reaction of hydrazones **1a** under the standard conditions. The product **5a** was not produced, but products **8** and **9** were formed in 25% and 71% yields, respectively (Scheme 3, b). This meant that the reaction proceeded in radical manner, and the radical **10** was the major intermediate (Scheme 4).

Based on the experimental results and literature,¹⁷ a mechanism was proposed finally. As showed in Scheme 4, a trifluoromethyl copper complex **11** was formed firstly when TMSCF₃ was stirred with CuOAc and CsF.¹⁸ The decomposition of TCCA afforded chlorine radical **12** and radical **13**, which abstracted a hydrogen from hydrazone **1a** to produce radical **14**. TCCA was finally converted into isocyanuric acid, which was detected from reaction mixture. Cyclization of radical **14** afforded carbon radical **10**, which combined the trifluoromethyl group from complex **11** to give the final product **5a**.

Scheme 3. Control Experiments for Mechanism



Scheme 4. Proposed Mechanism



CONCLUSIONS

51
52
53
54
55
56
57
58
59
60

In summary, an efficient cascade cyclization/trifluoromethylation reaction of β,γ -unsaturated hydrazones has been developed by using TMSCF_3 as CF_3 source and TCCA acid as promoter. Both

of the low cost and commercial availability of TMSCF_3 and TCCA make this process practical for preparation of trifluoroethyl pyrazolines. It is further demonstrated that TCCA can be an effective promoter for trifluoromethylation by using TMSCF_3 as trifluoromethylating reagent.

EXPERIMENTAL SECTION

General Methods. All reactions were performed in flame-dried glassware with magnetic stirring bar and sealed with a rubber septum. The solvents were distilled by standard methods. Reagents were obtained from commercial suppliers and used without further purification unless otherwise noted. Silica gel column chromatography was carried out using silica Gel 60 (230–400 mesh). Analytical thin layer chromatography (TLC) was done using silica Gel (silica gel 60 F254). TLC plates were analyzed by an exposure to ultraviolet (UV) light and/or submersion in phosphomolybdic acid solution or submersion in KMnO_4 solution or in Iodine vapor. NMR experiments were carried out in deuteriochloroform (CDCl_3) or deuterated acetone ($(\text{CD}_3)_2\text{CO}$). ^1H NMR, $^{13}\text{C}\{^1\text{H}\}$ NMR spectra were recorded at 400 MHz or 600 MHz and 100 MHz or 150 MHz spectrometers, respectively. ^{19}F NMR spectra were recorded at 376 MHz or 564 MHz spectrometers. Chemical shifts are reported as δ values relative to internal TMS (δ 0.00 for ^1H NMR), chloroform (δ 7.26 for ^1H NMR), acetone (δ 2.05 for ^1H NMR), chloroform (δ 77.00 for $^{13}\text{C}\{^1\text{H}\}$ NMR), and acetone (δ 206.26 for $^{13}\text{C}\{^1\text{H}\}$ NMR) in parts per million (ppm). The following abbreviations are used for the multiplicities: s: singlet, d: doublet, dd: doublet of doublet, t: triplet, q: quartet, m: multiplet, br: broad signal for proton spectra; Coupling constants (J) are reported in Hertz (Hz). Melting points were uncorrected. High resolution mass spectra (HRMS) were recorded on MicroTOF-QII mass instrument (ESI).

General Procedure for the Synthesis of CF_3 -Containing Pyrazolines 5. Under argon atmosphere, TMSCF_3 (179.0 mg, 1.3 mmol, 4.2 equiv) was added into a suspension of CuOAc

(129.0 mg, 1.1 mmol, 3.5 equiv) and CsF (191.0 mg, 1.3 mmol, 4.2 equiv) in dried MeCN (4 mL) at room temperature. After the reaction mixture was stirred at room temperature for 30 min, TCCA (0.2 mmol, 0.67 equiv) was added into the reaction mixture followed by addition of hydrazones **1** (0.3 mmol) immediately. The mixture was stirred at room temperature, and the reaction was monitored by thin layer chromatography (TLC) until the starting material was not detected. The reaction mixture was then quenched with water and extracted with ethyl acetate (3 × 5 mL). The combined organic layer was dried over Na₂SO₄, and the solvent was evaporated off under vacuum. The residue was purified by silica gel column chromatography (petroleum ether : EtOAc = 3 : 1) to afford the desired products **5** and by-products **6**.

3-Phenyl-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5a): 92 mg, 80% yield, white solid, mp 167–169 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.80 (d, *J* = 8.4, 2H), 7.66 (d, *J* = 7.2, 2H), 7.44–7.38 (m, 3H), 7.31 (d, *J* = 7.8, 2H), 3.93–3.87 (m, 1H), 3.51–3.42 (m, 1H), 3.30 (dd, *J* = 17.4, 10.8 Hz, 1H), 3.01 (dd, *J* = 17.4, 10.2 Hz, 1H), 2.61–2.52 (m, 1H), 2.40 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 157.6, 144.8, 130.9, 130.8, 130.2, 129.7, 128.9, 128.7, 126.9, 125.6 (q, *J* = 275.4 Hz), 56.8 (q, *J* = 3.0 Hz), 40.1 (q, *J* = 27.0 Hz), 40.0, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -64.55 (t, *J* = 10.9 Hz); HRMS (ESI): calcd for C₁₈H₁₇F₃N₂O₂SNa [M + Na]⁺ 405.0855, found 405.0854.

*3-(*m*-Tolyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5b)*: 77 mg, 65% yield, white solid, mp 151–153 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.81 (d, *J* = 8.4, 2H), 7.50 (s, 1H), 7.43 (d, *J* = 7.8, 1H), 7.31 (d, *J* = 7.8, 2H), 7.27 (t, *J* = 7.8, 1H), 7.24 (d, *J* = 7.2, 1H), 3.90–3.84 (m, 1H), 3.50–3.41 (m, 1H), 3.29 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.99 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.60–2.50 (m, 1H), 2.40 (s, 3H), 2.37 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 157.7, 144.7, 138.5, 131.7, 130.8, 130.1, 129.7, 128.9, 128.6, 127.4, 125.6 (q, *J* = 275.3 Hz), 124.1, 56.7 (q, *J* = 3.0 Hz), 40.1 (q, *J* = 27.6 Hz), 40.0, 21.6, 21.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -64.55 (t, *J* = 10.9 Hz); HRMS (ESI): calcd for C₁₉H₁₉F₃N₂O₂SNa [M + Na]⁺ 419.1012, found 419.1017.

1 *3-(p-Tolyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5c)*: 77 mg, 65% yield, white
2
3 solid, mp 170–171 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 8.4, 2H), 7.55 (d, *J* = 8.4, 2H),
4
5 7.30 (d, *J* = 8.0, 2H), 7.19 (d, *J* = 8.0, 2H), 3.90–3.81 (m, 1H), 3.52–3.39 (m, 1H), 3.28 (dd, *J* = 17.2,
6
7 10.8 Hz, 1H), 2.98 (dd, *J* = 17.2, 10.4 Hz, 1H), 2.63–2.51 (m, 1H), 2.39 (s, 3H), 2.37 (s, 3H); ¹³C{¹H}
8
9 NMR (150 MHz, CDCl₃) δ 157.6, 144.7, 141.4, 130.8, 129.7, 129.4, 128.4, 127.5, 126.9, 125.6 (q, *J*
10
11 = 275.7 Hz), 56.7 (q, *J* = 2.9 Hz), 40.1 (q, *J* = 27.2 Hz), 40.0, 21.6, 21.5; ¹⁹F NMR (376 MHz,
12
13 CDCl₃) δ -64.56 (t, *J* = 10.9 Hz); HRMS (ESI): calcd for C₁₉H₁₉F₃N₂O₂SNa [M + Na]⁺ 419.1012,
14
15 found 419.1021.

16
17
18
19
20 *3-(4-Methoxyphenyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5d)*: 90 mg, 73%
21
22 yield, white solid, mp 191–193 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.79 (d, *J* = 8.4, 2H), 7.60 (d, *J* =
23
24 8.4, 2H), 7.30 (d, *J* = 8.4, 2H), 6.89 (d, *J* = 8.4, 2H), 3.88–3.84 (m, 1H), 3.83 (s, 3H), 3.49–3.40 (m,
25
26 1H), 3.26 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.98 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.59–2.50 (m, 1H), 2.40 (s,
27
28 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 161.7, 157.3, 144.7, 130.8, 129.6, 128.9, 128.6, 125.6 (q, *J*
29
30 = 275.6 Hz), 122.8, 114.1, 56.7 (q, *J* = 3.0 Hz), 55.4, 40.1 (q, *J* = 27.2 Hz), 40.0, 21.6; ¹⁹F NMR
31
32 (376 MHz, CDCl₃) δ -64.56 (t, *J* = 10.9 Hz); HRMS (ESI): calcd for C₁₉H₁₉F₃N₂O₃SNa [M + Na]⁺
33
34 435.0961, found 435.0968.

35
36
37
38
39
40 *3-(2-Chlorophenyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5e)*: 70 mg, 56%
41
42 yield, white solid, mp 125–127 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.82 (d, *J* = 8.4, 2H), 7.56–7.54
43
44 (m, 1H), 7.38–7.32 (m, 4H), 7.29–7.26 (m, 1H), 3.94–3.88 (m, 1H), 3.51–3.45 (m, 1H), 3.42 (dd, *J*
45
46 = 18.0, 10.2 Hz, 1H), 3.01 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.64–2.57 (m, 1H), 2.44 (s, 3H); ¹³C{¹H}
47
48 NMR (150 MHz, CDCl₃) δ 157.8, 145.0, 132.8, 131.3, 130.8, 130.6, 130.4, 129.7, 129.6, 129.0,
49
50 126.9, 125.5 (q, *J* = 275.4 Hz), 57.4 (q, *J* = 3.0 Hz), 43.0, 39.9 (q, *J* = 27.5 Hz), 21.6; ¹⁹F NMR (376
51
52 MHz, CDCl₃) δ -64.60 (t, *J* = 10.9 Hz); HRMS (ESI): calcd for C₁₈H₁₆ClF₃N₂O₂SNa [M + Na]⁺
53
54 439.0465, found 439.0470.

1 *3-(3-Chlorophenyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5f)*: 92 mg, 74%
2
3 yield, white solid, mp 165–166 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.79 (d, *J* = 8.4, 2H), 7.64 (t, *J* =
4 1.8 Hz, 1H), 7.52–7.50 (m, 1H), 7.40–7.38 (m, 1H), 7.33–7.31 (m, 3H), 3.95–3.89 (m, 1H),
5 3.50–3.41 (m, 1H), 3.28 (dd, *J* = 17.4, 10.8 Hz, 1H), 3.01 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.60–2.54 (m,
6 1H), 2.41 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 156.3, 145.0, 134.9, 132.0, 130.8, 130.7,
7 130.0, 129.8, 128.8, 126.8, 125.5 (q, *J* = 275.6 Hz), 125.0, 56.9 (q, *J* = 3.0 Hz), 40.0 (q, *J* = 27.5 Hz),
8 39.8, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -64.53 (t, *J* = 10.9 Hz); HRMS (ESI): calcd for
9 C₁₈H₁₆ClF₃N₂O₂SNa [M + Na]⁺ 439.0465, found 439.0469.

10
11
12
13
14
15
16
17
18
19
20 *3-(4-Chlorophenyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5g)*: 94 mg, 75%
21
22 yield, white solid, mp 136–138 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.79 (d, *J* = 8.4, 2H), 7.59 (d, *J* =
23 8.4, 2H), 7.36 (d, *J* = 8.4, 2H), 7.32 (d, *J* = 7.8, 2H), 3.93–3.87 (m, 1H), 3.50–3.42 (m, 1H), 3.28 (dd,
24 *J* = 16.8, 10.8 Hz, 1H), 2.98 (dd, *J* = 16.8, 10.8 Hz, 1H), 2.61–2.52 (m, 1H), 2.40 (s, 3H); ¹³C{¹H}
25 NMR (150 MHz, CDCl₃) δ 156.5, 144.9, 137.0, 130.8, 129.7, 129.0, 128.9, 128.7, 128.1, 125.5 (q, *J*
26 = 272.6 Hz), 57.0 (q, *J* = 3.0 Hz), 40.0 (q, *J* = 27.5 Hz), 39.8, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ
27 -64.56 (t, *J* = 10.5 Hz); HRMS (ESI): calcd for C₁₈H₁₆ClF₃N₂O₂SNa [M + Na]⁺ 439.0465, found
28 439.0468.

29
30
31
32
33
34
35
36
37
38
39
40 *3-(4-Fluorophenyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5h)*: 76 mg, 63%
41
42 yield, white solid, mp 206–207 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.79 (d, *J* = 8.4, 2H), 7.67–7.63
43 (m, 2H), 7.32 (d, *J* = 8.4, 2H), 7.09–7.05 (m, 2H), 3.93–3.87 (m, 1H), 3.50–3.41 (m, 1H), 3.28 (dd,
44 *J* = 17.4, 10.8 Hz, 1H), 2.99 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.61–2.51 (m, 1H), 2.40 (s, 3H); ¹³C{¹H}
45 NMR (150 MHz, CDCl₃) δ 165.8 (d, *J* = 250.7), 156.5, 144.9, 130.8, 129.7, 128.9 (d, *J* = 8.7), 128.8,
46 126.5 (d, *J* = 3.0 Hz), 125.6 (q, *J* = 275.4 Hz), 115.9 (d, *J* = 21.9), 56.9 (q, *J* = 3.3 Hz), 40.0 (q, *J* =
47 27.3 Hz), 39.9, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -64.55 (t, *J* = 10.5 Hz), -108.77; HRMS (ESI):
48 calcd for C₁₈H₁₆F₄N₂O₂SNa [M + Na]⁺ 423.0761, found 423.0763.

1 *3-(4-Bromophenyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5i)*: 105 mg, 76%
2
3 yield, white solid, mp 197–198 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.79 (d, *J* = 7.8, 2H), 7.52 (s, 4H),
4
5 7.32 (d, *J* = 7.8, 2H), 3.93–3.88 (m, 1H), 3.50–3.42 (m, 1H), 3.28 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.98
6
7 (dd, *J* = 17.4, 10.8 Hz, 1H), 2.61–2.51 (m, 1H), 2.40 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ
8
9 156.6, 144.9, 132.0, 130.8, 129.7, 129.1, 128.9, 128.3, 125.5 (q, *J* = 275.7 Hz), 125.4, 57.0 (q, *J* =
10
11 2.0 Hz), 40.0 (q, *J* = 27.5 Hz), 39.8, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -64.55 (t, *J* = 10.5 Hz);
12
13 HRMS (ESI): calcd for C₁₈H₁₆BrF₃N₂O₂SNa [M + Na]⁺ 482.9960, found 482.9967.
14
15

16
17
18 *1-Tosyl-5-(2,2,2-trifluoroethyl)-3-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-pyrazole (5j)*: 97
19
20 mg, 72% yield, white solid, mp 152–154 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.80 (d, *J* = 7.8 Hz, 2H),
21
22 7.77 (d, *J* = 8.4 Hz, 2H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 3.98–3.93 (m, 1H),
23
24 3.52–3.44 (m, 1H), 3.33 (dd, *J* = 16.8, 10.8 Hz, 1H), 3.02 (dd, *J* = 16.8, 10.2 Hz, 1H), 2.63–2.54 (m,
25
26 1H), 2.41 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 156.1, 145.1, 133.5, 132.5 (q, *J* = 32.7 Hz),
27
28 130.8, 129.8, 128.8, 127.1, 125.7 (q, *J* = 3.6 Hz), 125.5 (q, *J* = 275.1 Hz), 123.7 (q, *J* = 271.0 Hz),
29
30 57.1 (q, *J* = 3.2 Hz), 40.0 (q, *J* = 27.5 Hz), 39.8, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -63.39, -64.54
31
32 (t, *J* = 10.5 Hz); HRMS (ESI): calcd for C₁₉H₁₆F₆N₂O₂SNa [M + Na]⁺ 473.0729, found 473.0735.
33
34
35

36
37
38 *3-(Thiophen-2-yl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5k)*: 54 mg, 46%
39
40 yield, white solid, mp 124–125 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.78 (d, *J* = 7.8 Hz, 2H),
41
42 7.44–7.43 (m, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.18–7.17 (m, 1H), 7.03–7.02 (m, 1H), 3.90–3.84 (m,
43
44 1H), 3.47–3.39 (m, 1H), 3.26 (dd, *J* = 17.4, 10.8 Hz, 1H), 3.01 (dd, *J* = 16.8, 10.8 Hz, 1H),
45
46 2.60–2.51 (m, 1H), 2.40 (s, 3H); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 153.1, 144.8, 133.6, 130.6,
47
48 129.7, 129.6, 129.4, 129.0, 127.5, 125.5 (q, *J* = 275.6 Hz), 56.9 (q, *J* = 3.2 Hz), 40.6, 39.9 (q, *J* =
49
50 27.5 Hz), 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -64.57 (t, *J* = 10.5 Hz); HRMS (ESI): calcd for
51
52 C₁₆H₁₅F₃N₂O₂S₂Na [M + Na]⁺ 411.0419, found 411.0434.
53
54
55

56
57 *tert-Butyl 3-(1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazol-3-yl)-1H-indole-1-*
58
59
60

1 *carboxylate (5l)*: 117 mg, 75% yield, white solid, mp 165–167 °C; ^1H NMR (600 MHz, CDCl_3) δ
2
3 8.34 (d, $J = 7.2$ Hz, 1H), 8.12 (d, $J = 7.2$ Hz, 1H), 7.83 (d, $J = 7.2$ Hz, 2H), 7.66 (s, 1H), 7.43–7.38
4
5 (m, 2H), 7.26 (d, $J = 6.6$ Hz, 2H), 3.89–3.83 (m, 1H), 3.53–3.45 (m, 1H), 3.30 (dd, $J = 16.8, 10.8$ Hz,
6
7 1H), 3.04 (dd, $J = 16.8, 10.8$ Hz, 1H), 2.62–2.52 (m, 1H), 2.36 (s, 3H), 1.67 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR
8
9 (150 MHz, CDCl_3) δ 153.1, 149.0, 144.7, 135.7, 130.7, 129.7, 128.9, 127.8, 126.9, 125.7, 125.6 (q, J
10
11 = 275.7 Hz), 124.1, 122.9, 115.1, 112.8, 85.0, 55.9 (q, $J = 3.3$ Hz), 40.7, 40.0 (q, $J = 27.2$ Hz), 28.1,
12
13 21.6; ^{19}F NMR (376 MHz, CDCl_3) δ -64.54 (t, $J = 10.5$ Hz); HRMS (ESI): calcd for
14
15 $\text{C}_{25}\text{H}_{26}\text{F}_3\text{N}_3\text{O}_4\text{SNa}$ $[\text{M} + \text{Na}]^+$ 544.1488, found 544.1490.

16
17
18
19
20 *3-(tert-Butyl)-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5m)*: 96 mg, 88% yield,
21
22 white solid, mp 119–120 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.32 (d, $J = 8.4$
23
24 Hz, 2H), 3.66–3.61 (m, 1H), 3.37–3.28 (m, 1H), 2.82 (dd, $J = 17.4, 10.2$ Hz, 1H), 2.56 (dd, $J = 17.4,$
25
26 10.8 Hz, 1H), 2.49–2.44 (m, 1H), 2.43 (s, 3H), 1.06 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ
27
28 169.8, 144.6, 130.3, 129.3, 129.1, 125.6 (q, $J = 275.4$ Hz), 56.8 (q, $J = 3.0$ Hz), 40.0 (q, $J = 27.3$ Hz),
29
30 39.0, 34.2, 27.7, 21.6; ^{19}F NMR (376 MHz, CDCl_3) δ -64.69 (t, $J = 10.9$ Hz); HRMS (ESI): calcd for
31
32 $\text{C}_{16}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_2\text{SNa}$ $[\text{M} + \text{Na}]^+$ 385.1171, found 385.1168.

33
34
35
36
37 *3-Cyclohexyl-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5n)*: 69 mg, 59% yield,
38
39 white solid, mp 144–145 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.33 (d, $J = 8.4$
40
41 Hz, 2H), 3.67–3.61 (m, 1H), 3.37–3.29 (m, 1H), 2.78 (dd, $J = 17.4, 10.2$ Hz, 1H), 2.57 (dd, $J = 17.4,$
42
43 10.2 Hz, 1H), 2.48–2.39 (m, 4H), 2.28–2.24 (m, 1H), 1.75–1.65 (m, 5H), 1.30–1.13 (m, 5H);
44
45 $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 166.6, 144.6, 130.5, 129.4, 129.0, 125.6 (q, $J = 275.6$ Hz), 56.0
46
47 (q, $J = 3.0$ Hz), 40.5, 40.0 (q, $J = 27.3$ Hz), 39.1, 30.2, 29.8, 25.7, 25.6, 25.5, 21.6; ^{19}F NMR (376
48
49 MHz, CDCl_3) δ -64.69 (t, $J = 10.5$ Hz); HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_2\text{SNa}$ $[\text{M} + \text{Na}]^+$
50
51 411.1325, found 411.1332.

52
53
54
55
56
57 *3-Isopropyl-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5o)*: 72 mg, 69% yield,
58
59
60

white solid, mp 118–119 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.33 (d, $J = 8.4$ Hz, 2H), 3.69–3.63 (m, 1H), 3.38–3.29 (m, 1H), 2.79 (dd, $J = 17.4, 10.2$ Hz, 1H), 2.60–2.54 (m, 2H), 2.50–2.40 (m, 4H), 1.05 (d, $J = 6.6$ Hz, 3H), 1.04 (d, $J = 6.6$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 167.4, 144.6, 130.5, 129.4, 129.0, 125.6 (q, $J = 275.4$ Hz), 56.3 (q, $J = 3.0$ Hz), 40.1, 40.0 (q, $J = 27.3$ Hz), 29.7, 21.6, 19.9, 19.5; ^{19}F NMR (376 MHz, CDCl_3) δ -64.71 (t, $J = 10.9$ Hz); HRMS (ESI): calcd for $\text{C}_{15}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_2\text{SNa}$ [$\text{M} + \text{Na}$] $^+$ 371.1012, found 371.1009.

3-Phenethyl-1-tosyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole (5p): 75 mg, 61% yield, white solid, mp 64–66 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.72 (d, $J = 8.4$ Hz, 2H), 7.32 (d, $J = 8.4$ Hz, 2H), 7.26–7.20 (m, 3H), 7.05 (d, $J = 7.2$ Hz, 2H), 3.72–3.63 (m, 1H), 3.39–3.26 (m, 1H), 2.90–2.81 (m, 1H), 2.76 (dd, $J = 14.0, 7.6$ Hz, 1H), 2.69 (dd, $J = 17.6, 10.4$ Hz, 1H), 2.62–2.49 (m, 3H), 2.45 (s, 3H), 2.43–2.34 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 162.2, 144.7, 140.1, 130.7, 129.6, 128.9, 128.5, 128.1, 126.4, 125.5 (q, $J = 275.3$ Hz), 56.1 (q, $J = 3.2$ Hz), 42.7, 39.9 (q, $J = 27.2$ Hz), 32.4, 31.5, 21.6; ^{19}F NMR (376 MHz, CDCl_3) δ -64.70 (t, $J = 10.5$ Hz); HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_2\text{SNa}$ [$\text{M} + \text{Na}$] $^+$ 433.1168, found 433.1175.

Benzyl 3-phenyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5aa): 74 mg, 68% yield, white solid, mp 119–120 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.76–7.73 (m, 2H), 7.47–7.32 (m, 8H), 5.37–5.29 (m, 2H), 4.75–4.67 (m, 1H), 3.52 (dd, $J = 18.0, 11.2$ Hz, 1H), 3.18 (dd, $J = 17.6, 5.6$ Hz, 1H), 3.04 (br, 1H), 2.41–2.24 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 154.3, 152.7, 135.9, 130.8, 130.5, 128.6, 128.5, 128.3, 128.2, 126.7, 125.6 (q, $J = 275.9$ Hz), 67.8, 53.0, 38.4, 37.5; ^{19}F NMR (376 MHz, CDCl_3) δ -63.71; HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{17}\text{F}_3\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 385.1134, found 385.1141.

*Benzyl 3-(*m*-tolyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ab)*: 62 mg, 55% yield, white solid, mp 140–141 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.60 (s, 1H), 7.50 (d, $J = 7.8$ Hz, 1H), 7.46 (d, $J = 7.8$ Hz, 2H), 7.38 (t, $J = 7.2$ Hz, 2H), 7.35–7.32 (m, 1H), 7.29 (t, $J = 7.8$ Hz,

1H), 7.23 (d, $J = 7.8$ Hz, 1H), 5.36–5.30 (m, 2H), 4.72–4.67 (m, 1H), 3.50 (dd, $J = 17.4, 11.4$ Hz, 1H), 3.17 (dd, $J = 18.0, 5.4$ Hz, 1H), 3.03 (br, 1H), 2.38 (s, 3H), 2.35–2.28 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 154.5, 152.7, 138.4, 136.0, 131.3, 130.7, 128.6, 128.5, 128.3, 128.2, 127.2, 125.6 (q, $J = 275.4$ Hz), 124.0, 67.9, 53.0, 38.5, 37.5, 21.2; ^{19}F NMR (376 MHz, CDCl_3) δ -68.45; HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 399.1291, found 399.1293.

Benzyl 3-(p-tolyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ac): 70 mg, 62% yield, white solid, mp 158–159 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.63 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 7.2$ Hz, 2H), 7.38 (t, $J = 7.2$ Hz, 2H), 7.35–7.32 (m, 1H), 7.21 (d, $J = 7.8$ Hz, 2H), 5.36–5.30 (m, 2H), 4.71–4.66 (m, 1H), 3.48 (dd, $J = 17.4, 10.8$ Hz, 1H), 3.15 (dd, $J = 17.4, 5.4$ Hz, 1H), 3.04 (br, 1H), 2.38 (s, 3H), 2.35–2.25 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 154.4, 152.7, 140.8, 136.0, 129.3, 128.5, 128.3, 128.2, 128.1, 126.7, 125.6 (q, $J = 275.9$ Hz), 67.8, 53.0, 38.4, 37.5, 21.4; ^{19}F NMR (376 MHz, CDCl_3) δ -68.47; HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 399.1291, found 399.1294.

Benzyl 3-(4-methoxyphenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ad): 67 mg, 57% yield, white solid, mp 151–152 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, $J = 8.4$ Hz, 2H), 7.45 (d, $J = 7.6$ Hz, 2H), 7.40–7.33 (m, 3H), 6.91 (d, $J = 8.4$ Hz, 2H), 5.36–5.29 (m, 2H), 4.71–4.65 (m, 1H), 3.84 (s, 3H), 3.49 (dd, $J = 17.6, 11.2$ Hz, 1H), 3.14 (dd, $J = 18.0, 5.6$ Hz, 1H), 3.04 (br, 1H), 2.37–2.23 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 161.5, 154.1, 152.4, 136.0, 128.5, 128.4, 128.3, 128.2, 128.1, 125.6 (q, $J = 275.9$ Hz), 123.4, 67.8, 55.4, 52.9, 38.5, 37.4; ^{19}F NMR (376 MHz, CDCl_3) δ -63.72; HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{20}\text{F}_3\text{N}_2\text{O}_3$ $[\text{M} + \text{H}]^+$ 393.1421, found 393.1417.

Benzyl 3-(3-methoxyphenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ae): 74 mg, 63% yield, white solid, mp 135–136 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.45 (d, $J = 7.2$ Hz, 2H), 7.39–7.36 (m, 2H), 7.34–7.30 (m, 3H), 7.26–7.25 (m, 1H), 6.98–6.96 (m, 1H), 5.35–5.30 (m,

2H), 4.72–4.67 (m, 1H), 3.84 (s, 3H), 3.50 (dd, $J = 17.4, 11.4$ Hz, 1H), 3.16 (dd, $J = 17.4, 5.4$ Hz, 1H), 3.02 (br, 1H), 2.35–2.26 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 159.7, 154.3, 152.5, 135.9, 132.1, 129.7, 128.6, 128.3, 128.2, 125.6 (q, $J = 275.7$ Hz), 119.4, 116.8, 111.5, 67.9, 55.4, 53.0, 38.5, 37.4; ^{19}F NMR (376 MHz, CDCl_3) δ -63.72; HRMS (ESI): calcd for $\text{C}_{20}\text{H}_{19}\text{F}_3\text{N}_2\text{O}_3\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 415.1240, found 415.1236.

Benzyl 3-(3-chlorophenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5af): 60 mg, 50% yield, white solid, mp 120–121 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.74 (s, 1H), 7.60 (d, $J = 7.2$ Hz, 1H), 7.45 (d, $J = 7.8$ Hz, 2H), 7.40–7.38 (m, 3H), 7.35–7.33 (m, 2H), 5.36–5.30 (m, 2H), 4.74–4.69 (m, 1H), 3.49 (dd, $J = 18.0, 11.4$ Hz, 1H), 3.14 (dd, $J = 18.0, 5.4$ Hz, 1H), 3.03 (br, 1H), 2.37–2.28 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 152.9, 152.6, 135.8, 134.8, 132.6, 130.4, 129.9, 128.6, 128.4, 128.3, 126.7, 125.5 (q, $J = 275.9$ Hz), 124.8, 68.0, 53.3, 38.3, 37.4; ^{19}F NMR (376 MHz, CDCl_3) δ -68.45; HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{16}\text{ClF}_3\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 419.0745, found 419.0749.

Benzyl 3-(4-chlorophenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ag): 69 mg, 58% yield, white solid, mp 136–137 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.8$ Hz, 2H), 7.45 (d, $J = 6.8$ Hz, 2H), 7.41–7.32 (m, 5H), 5.36–5.29 (m, 2H), 4.75–4.67 (m, 1H), 3.49 (dd, $J = 18.0, 11.2$ Hz, 1H), 3.15 (dd, $J = 18.0, 5.6$ Hz, 1H), 3.03 (br, 1H), 2.39–2.25 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 153.2, 152.5, 136.5, 135.9, 129.4, 129.0, 128.6, 128.4, 128.3, 128.0, 125.6 (q, $J = 276.0$ Hz), 68.0, 53.2, 38.4, 37.5; ^{19}F NMR (376 MHz, CDCl_3) δ -68.47; HRMS (ESI): calcd for $\text{C}_{19}\text{H}_{16}\text{ClF}_3\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 419.0745, found 419.0748.

Benzyl 3-(3-fluorophenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ah): 40 mg, 35% yield, white solid, mp 114–115 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.49–7.45 (m, 4H), 7.40–7.33 (m, 4H), 7.13–7.10 (m, 1H), 5.35–5.30 (m, 2H), 4.75–4.70 (m, 1H), 3.50 (dd, $J = 17.4, 10.8$ Hz, 1H), 3.15 (dd, $J = 18.0, 5.4$ Hz, 1H), 3.04 (br, 1H), 2.37–2.28 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150

MHz, CDCl₃) δ 162.8 (d, J = 245.4 Hz), 153.1, 152.6, 135.8, 133.0 (d, J = 8.1 Hz), 130.3 (d, J = 8.1 Hz), 128.6, 128.4, 128.3, 125.5 (q, J = 275.9 Hz), 122.5 (d, J = 3.0 Hz), 117.4 (d, J = 21.3 Hz), 113.5 (d, J = 23.1 Hz), 68.0, 53.2, 38.3, 37.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -63.72, -112.59; HRMS (ESI): calcd for C₁₉H₁₆F₄N₂O₂Na [M + Na]⁺ 403.1040, found 403.1048.

Benzyl 3-(thiophen-2-yl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ai): 64 mg, 58% yield, white solid, mp 124–125 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.45–7.42 (m, 3H), 7.40–7.31 (m, 3H), 7.26 (d, J = 3.2 Hz, 1H), 7.07–7.05 (m, 1H), 5.35–5.27 (m, 2H), 4.73–4.65 (m, 1H), 3.52 (dd, J = 17.6, 11.2 Hz, 1H), 3.17 (dd, J = 17.6, 5.6 Hz, 1H), 3.02 (br, 1H), 2.38–2.24 (m, 1H); ¹³C {¹H} NMR (150 MHz, CDCl₃) δ 152.5, 149.9, 135.9, 134.3, 129.0, 128.8, 128.5, 128.3, 128.2, 127.5, 125.5 (q, J = 275.9 Hz), 67.9, 53.1, 39.2, 37.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -63.73; HRMS (ESI): calcd for C₁₇H₁₅F₃N₂O₂SNa [M + Na]⁺ 391.0699, found 391.0708.

Methyl 3-phenyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5aj): 52 mg, 61% yield, white solid, mp 122–123 °C; ¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, J = 7.8 Hz, 2H), 7.44–7.39 (m, 3H), 4.72–4.67 (m, 1H), 3.90 (s, 3H), 3.53 (dd, J = 18.0, 11.4 Hz, 1H), 3.01 (dd, J = 18.0, 5.4 Hz, 1H), 3.08 (br, 1H), 2.37–2.28 (m, 1H); ¹³C {¹H} NMR (150 MHz, CDCl₃) δ 154.4, 153.3, 130.7, 130.5, 128.7, 126.7, 125.6 (q, J = 275.7 Hz), 53.4, 53.0 (q, J = 2.9 Hz), 38.3, 37.3; ¹⁹F NMR (376 MHz, CDCl₃) δ -63.68 (t, J = 10.9 Hz); HRMS (ESI): calcd for C₁₃H₁₃F₃N₂O₂Na [M + Na]⁺ 309.0821, found 309.0811.

Methyl 3-(p-tolyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ak): 50 mg, 55% yield, white solid, mp 147–149 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 4.72–4.64 (m, 1H), 3.90 (s, 3H), 3.51 (dd, J = 17.6, 11.2 Hz, 1H), 3.16 (dd, J = 18.0, 5.6 Hz, 1H), 3.08 (br, 1H), 2.38 (s, 3H), 2.36–2.67 (m, 1H); ¹³C {¹H} NMR (150 MHz, CDCl₃) δ 154.5, 153.3, 140.9, 129.4, 127.9, 125.7, 125.6 (q, J = 275.9 Hz), 53.4, 52.9 (q, J = 3.3 Hz), 38.4, 37.4, 21.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -68.88 (t, J = 10.5 Hz); HRMS (ESI): calcd for

1 $C_{14}H_{15}F_3N_2O_2Na$ [M + Na]⁺ 323.0978, found 323.0978.

2
3 *Methyl 3-(4-bromophenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5al)*:
4
5 61 mg, 56% yield, white solid, mp 112–113 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, *J* = 8.8 Hz,
6 2H), 7.54 (d, *J* = 8.4 Hz, 2H), 4.74–4.67 (m, 1H), 3.90 (s, 3H), 3.51 (dd, *J* = 18.0, 11.2 Hz, 1H), 3.16
7 (dd, *J* = 18.0, 5.6 Hz, 1H), 3.08 (br, 1H), 2.40–2.26 (m, 1H); ¹³C {¹H} NMR (150 MHz, CDCl₃) δ
8 153.3, 153.2, 131.9, 129.7, 128.1, 125.6 (q, *J* = 275.9 Hz), 124.9, 53.5, 53.0 (q, *J* = 3.2 Hz), 38.2,
9 37.4; ¹⁹F NMR (376 MHz, CDCl₃) δ -63.67 (t, *J* = 10.5 Hz); HRMS (ESI): calcd for
10 $C_{13}H_{12}BrF_3N_2O_2Na$ [M + Na]⁺ 386.9926, found 386.9917.

11
12
13
14
15
16
17
18
19
20 *Methyl 3-(tert-butyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5am)*: 36
21 mg, 45% yield, colorless oil; ¹H NMR (400 MHz, CDCl₃) δ 4.55–4.48 (m, 1H), 3.83 (s, 3H), 3.11
22 (dd, *J* = 18.0, 11.2 Hz, 1H), 2.95 (br, 1H), 2.78 (dd, *J* = 18.0, 5.2 Hz, 1H), 2.28–2.14 (m, 1H), 1.21 (s,
23 9H); ¹³C {¹H} NMR (150 MHz, CDCl₃) δ 166.0, 153.4, 125.6 (q, *J* = 275.9 Hz), 53.3, 52.6 (q, *J* =
24 2.9 Hz), 37.3, 37.0 (q, *J* = 23.1 Hz), 34.0, 27.9; ¹⁹F NMR (376 MHz, CDCl₃) δ -63.66 (t, *J* = 10.5
25 Hz); HRMS (ESI): calcd for $C_{11}H_{17}F_3N_2O_2Na$ [M + Na]⁺ 289.1134, found 289.1128.

26
27
28
29
30
31
32
33
34
35 *tert-Butyl 3-phenyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5an)*: 66 mg,
36 67% yield, white solid, mp 113–114 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 3.6 Hz, 2H),
37 7.41–7.39 (m, 3H), 4.68–4.62 (m, 1H), 3.51 (dd, *J* = 18.0, 11.6 Hz, 1H), 3.14 (dd, *J* = 18.0, 5.2 Hz,
38 1H), 2.97 (br, 1H), 2.37–2.24 (m, 1H), 1.58 (s, 9H); ¹³C {¹H} NMR (150 MHz, CDCl₃) δ 153.3,
39 151.7, 131.1, 130.2, 128.6, 126.6, 125.7 (q, *J* = 272.4 Hz), 82.1, 52.8 (q, *J* = 3.0 Hz), 38.6, 38.0, 28.3;
40 ¹⁹F NMR (376 MHz, CDCl₃) δ -68.75; HRMS (ESI): calcd for $C_{16}H_{19}F_3N_2O_2Na$ [M + Na]⁺
41 351.1291, found 351.1297.

42
43
44
45
46
47
48
49
50
51
52 *tert-Butyl 3-(p-tolyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (5ao)*: 60 mg,
53 58% yield, white solid, mp 117–118 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.63 (d, *J* = 7.6 Hz, 2H), 7.63
54 (d, *J* = 7.6 Hz, 2H), 4.65–4.60 (m, 1H), 3.48 (dd, *J* = 17.6, 11.2 Hz, 1H), 3.12 (dd, *J* = 17.6, 5.6 Hz,
55 2H), 2.37–2.24 (m, 1H), 1.58 (s, 9H); ¹³C {¹H} NMR (150 MHz, CDCl₃) δ 153.3,
56 151.7, 131.1, 130.2, 128.6, 126.6, 125.7 (q, *J* = 272.4 Hz), 82.1, 52.8 (q, *J* = 3.0 Hz), 38.6, 38.0, 28.3;
57 ¹⁹F NMR (376 MHz, CDCl₃) δ -68.75; HRMS (ESI): calcd for $C_{16}H_{19}F_3N_2O_2Na$ [M + Na]⁺
58 351.1291, found 351.1297.

1H), 2.95 (br, 1H), 2.37 (s, 3H), 2.33–2.22 (m, 1H), 1.57 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 153.3, 151.6, 140.5, 129.8, 128.3, 126.6, 125.7 (q, $J = 275.8$ Hz), 82.0, 52.7 (q, $J = 2.5$ Hz), 38.7, 37.8, 28.3, 21.4; ^{19}F NMR (376 MHz, CDCl_3) δ -64.01; HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 365.1447, found 365.1449.

tert-Butyl 3-(4-bromophenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (**5ap**): 67 mg, 55% yield, white solid, mp 125–127 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.60 (d, $J = 8.4$ Hz, 2H), 7.53 (d, $J = 8.4$ Hz, 2H), 4.68–4.61 (m, 1H), 3.48 (dd, $J = 17.6, 11.2$ Hz, 1H), 3.11 (dd, $J = 17.6, 5.6$ Hz, 1H), 2.96 (br, 1H), 2.38–2.24 (m, 1H), 1.57 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 152.2, 151.4, 131.8, 130.1, 128.1, 125.6 (q, $J = 275.9$ Hz), 124.6, 82.3, 53.0 (q, $J = 3.3$ Hz), 38.5, 38.0, 28.3; ^{19}F NMR (376 MHz, CDCl_3) δ -63.99; HRMS (ESI): calcd for $\text{C}_{16}\text{H}_{18}\text{BrF}_3\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 429.0396, found 429.0408.

tert-Butyl 3-(4-chlorophenyl)-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazole-1-carboxylate (**5aq**): 65 mg, 53% yield, white solid, mp 110–111 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.8$ Hz, 2H), 7.36 (d, $J = 8.8$ Hz, 2H), 4.69–4.61 (m, 1H), 3.48 (dd, $J = 17.6, 11.2$ Hz, 1H), 3.11 (dd, $J = 17.6, 5.2$ Hz, 1H), 2.97 (br, 1H), 2.38–2.24 (m, 1H), 1.57 (s, 9H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 152.1, 136.2, 129.6, 128.9, 127.9, 125.6 (q, $J = 275.9$ Hz), 82.3, 53.0 (q, $J = 3.2$ Hz), 38.5, 38.0, 28.3; ^{19}F NMR (376 MHz, CDCl_3) δ -63.97; HRMS (ESI): calcd for $\text{C}_{16}\text{H}_{18}\text{ClF}_3\text{N}_2\text{O}_2\text{Na}$ [$\text{M} + \text{Na}$] $^+$ 385.0901, found 385.0902.

1-(3-Phenyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazol-1-yl)ethan-1-one (**5ar**): 22 mg, 27% yield, white solid, mp 120–121 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.73 (d, $J = 8.4$ Hz, 2H), 7.46–7.42 (m, 3H), 4.86–4.81 (m, 1H), 3.49 (dd, $J = 18.0, 11.4$ Hz, 1H), 3.20 (dd, $J = 18.0, 5.4$ Hz, 1H), 3.17–3.11 (m, 1H), 2.39 (s, 3H), 2.33–2.24 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 169.5, 154.3, 131.0, 130.6, 128.8, 126.5, 125.7 (q, $J = 275.7$ Hz), 51.6 (q, $J = 3.2$ Hz), 38.0, 36.4 (q, $J = 26.9$ Hz), 22.1; ^{19}F NMR (376 MHz, CDCl_3) δ -68.20 (t, $J = 10.9$ Hz); HRMS (ESI): calcd for

$C_{13}H_{13}F_3N_2ONa$ $[M + Na]^+$ 293.0872, found 293.0881.

2-Methyl-1-(3-phenyl-5-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-pyrazol-1-yl)propan-1-one (5as): 30 mg, 34% yield, white solid, mp 86–87 °C; 1H NMR (600 MHz, $CDCl_3$) δ 7.74–7.72 (m, 2H), 7.46–7.41 (m, 3H), 4.85–4.80 (m, 1H), 3.50–3.42 (m, 2H), 3.18 (dd, $J = 18.0, 5.4$ Hz, 1H), 3.15–3.06 (m, 1H), 2.33–2.24 (m, 1H), 1.23 (d, $J = 7.2$ Hz, 3H), 1.18 (d, $J = 6.6$ Hz, 3H); $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$) δ 176.0, 154.0, 131.1, 130.4, 128.7, 126.5, 125.8 (q, $J = 275.9$ Hz), 51.7 (q, $J = 3.0$ Hz), 37.7, 36.4 (q, $J = 26.9$ Hz), 32.0, 18.9, 18.6; ^{19}F NMR (376 MHz, $CDCl_3$) δ -63.54 (t, $J = 10.9$ Hz); HRMS (ESI): calcd for $C_{15}H_{18}F_3N_2O$ $[M + H]^+$ 299.1366, found 299.1366.

5-(Chloromethyl)-3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazole (6a): 24 mg, 23% yield (Table 1, Entry 1), white solid, mp 126–127 °C; 1H NMR (600 MHz, $CDCl_3$) δ 7.80 (d, $J = 8.4$ Hz, 2H), 7.67 (d, $J = 7.2$ Hz, 2H), 7.43–7.37 (m, 3H), 7.29 (d, $J = 7.8$ Hz, 2H), 4.19–4.12 (m, 2H), 3.80–3.77 (m, 1H), 3.24 (dd, $J = 17.4, 10.8$ Hz, 1H), 3.17 (dd, $J = 17.4, 8.4$ Hz, 1H), 2.39 (s, 3H); $^{13}C\{^1H\}$ NMR (150 MHz, $CDCl_3$) δ 157.5, 144.6, 131.9, 130.8, 130.4, 129.6, 128.6, 128.5, 126.9, 61.9, 46.6, 38.6, 21.6; HRMS (ESI): calcd for $C_{17}H_{17}ClN_2O_2SNa$ $[M + Na]^+$ 371.0591, found 371.0599.

5-(Iodomethyl)-3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazole (6b): 58 mg, 44% yield, white solid, mp 141–142 °C; 1H NMR (400 MHz, $CDCl_3$) δ 7.80 (d, $J = 8.0$ Hz, 2H), 7.66 (d, $J = 6.8$ Hz, 2H), 7.44–7.36 (m, 3H), 7.30 (d, $J = 8.0$ Hz, 2H), 4.08–4.00 (m, 1H), 3.83 (dd, $J = 10.0, 3.2$ Hz, 1H), 3.45 (t, $J = 10.0$ Hz, 1H), 3.32 (dd, $J = 17.2, 10.8$ Hz, 1H), 3.00 (dd, $J = 17.6, 9.2$ Hz, 1H), 2.39 (s, 3H); $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 156.6, 144.6, 131.9, 130.8, 130.4, 129.7, 128.6, 128.5, 126.9, 62.2, 41.6, 21.6, 9.8; HRMS (ESI): calcd for $C_{17}H_{17}IN_2O_2SNa$ $[M + Na]^+$ 462.9948, found 462.9947.

5-(Bromomethyl)-3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazole (6c): 62 mg, 53% yield, white solid, mp 135–136 °C; 1H NMR (400 MHz, $CDCl_3$) δ 7.80 (d, $J = 8.0$ Hz, 2H), 7.67 (d, $J = 7.2$ Hz, 2H), 7.44–7.37 (m, 3H), 7.30 (d, $J = 8.0$ Hz, 2H), 4.20–4.12 (m, 1H), 4.00 (dd, $J = 10.0, 3.2$ Hz, 1H),

1 3.62 (t, $J = 9.6$ Hz, 1H), 3.28 (dd, $J = 17.6, 11.2$ Hz, 1H), 3.12 (dd, $J = 17.6, 8.8$ Hz, 1H), 2.39 (s,
2 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 157.3, 144.6, 131.7, 130.8, 130.3, 129.7, 128.6, 128.5,
3 126.9, 61.8, 39.7, 35.2, 21.6; HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{17}\text{BrN}_2\text{O}_2\text{SNa}$ $[\text{M} + \text{Na}]^+$ 415.0086, found
4 415.0094.
5
6
7
8
9

10 **General Procedure I for the Synthesis of Compound 7.** Substrate **5a** (76.48 mg, 0.20 mmol),
11 NaOH (16.00 mg, 0.40 mmol, 2.0 equiv) and MeOH (3.0 mL) were added to a flask equipped with a
12 magnetic stir bar under argon atmosphere. The mixture was stirred at 90 °C until the reaction was
13 completed as monitored by TLC analysis. The crude product was purified by flash chromatography
14 on silica gel (petroleumether : EtOAc = 3 : 1) directly to give the corresponding product **7** in 94%
15 yield as a white solid.
16
17
18
19
20
21
22
23
24

25 **General Procedure II for the Synthesis of Compound 7.** A solution of trifluoroethyl pyrazoline
26 **5an** (65.67 mg, 0.20 mmol) and CuCl_2 (80.67 mg, 0.60 mmol, 3.0 equiv) in EtOH (4.0 mL) was
27 stirred under reflux for 8 h. The reaction process was monitored by TLC until the starting material
28 disappeared. The reaction mixture was then cooled to room temperature, and the solid was filtered
29 off from the reaction mixture. The filtrate was concentrated under vacuum. The crude product was
30 purified by flash chromatography on silica gel (petroleumether : EtOAc = 3 : 1) directly to give the
31 corresponding product **7** in 65% yield as a white solid.
32
33
34
35
36
37
38
39
40
41

42 *3-Phenyl-5-(2,2,2-trifluoroethyl)-1H-pyrazole (7)*: 42 mg, 94% yield (Synthesized by Procedure I),
43 white solid, mp 118–120 °C; ^1H NMR (600 MHz, CDCl_3) δ 11.35 (br, 1H), 7.60 (d, $J = 7.2$ Hz, 2H),
44 7.43–7.40 (m, 2H), 7.37–7.34 (m, 1H), 6.54 (s, 1H), 3.45–3.41 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz,
45 CDCl_3) δ 146.1, 141.6, 129.7, 129.1, 128.7, 125.5, 125.3 (q, $J = 274.8$ Hz), 103.4, 32.9 (q, $J = 31.2$
46 Hz); ^{19}F NMR (376 MHz, CDCl_3) δ -70.78 (t, $J = 10.9$ Hz); HRMS (ESI): calcd for $\text{C}_{11}\text{H}_9\text{F}_3\text{N}_2\text{Na}$
47 $[\text{M} + \text{Na}]^+$ 249.0610, found 249.0613.
48
49
50
51
52
53
54
55
56

57 Control Experiments.

58
59
60

Reaction of 6a with TCCA, Me₃SiCF₃, CsF, CuOAc.

Under argon atmosphere, Me₃SiCF₃ (179.0 mg, 1.3 mmol, 4.2 equiv) was added to a suspension of CuOAc (129.0 mg, 1.1 mmol, 3.5 equiv) and CsF (191.0 mg, 1.3 mmol, 4.2 equiv) in dried MeCN (4 mL) at room temperature. After the reaction mixture was stirred at room temperature for 30 min, TCCA (47 mg, 0.2 mmol, 0.67 equiv) was added to the reaction mixture. Subsequently, **6a** (0.3 mmol) was added to the system. The mixture was stirred at room temperature and monitored by thin layer chromatography (TLC). No desired product **5a** was observed and **6a** was recovered in 94% yield.

Reaction of TEMPO with TCCA, Me₃SiCF₃, CsF, CuOAc, and 1a.

Under argon atmosphere, TMSCF₃ (179.0 mg, 1.3 mmol, 4.2 equiv) was added to a suspension of CuOAc (129.0 mg, 1.1 mmol, 3.5 equiv) and CsF (191.0 mg, 1.3 mmol, 4.2 equiv) and 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO, 94.0 mg, 0.6 mmol, 2.0 equiv) in dried MeCN (4 mL) at room temperature. After the reaction mixture was stirred at room temperature for 30 min, α,α,α -trifluorotoluene (internal standard, 44.0 mg, 0.3 mmol) and TCCA were added to the reaction mixture. Subsequently, hydrazones **1a** (0.3 mmol) was added to the system. ¹⁹F NMR analysis of this reaction mixture showed that TEMPO-CF₃ were formed in 25% and no desired product **5a** was observed. Then the reaction mixture was quenched with water and extracted with ethyl acetate (3 × 5 mL). The organic layer was dried over Na₂SO₄, and evaporated in vacuum. The residue was purified by silica gel column chromatography (petroleum ether : EtOAc = 5 : 1) to afford the compound **9** in 71% yield.

2,2,6,6-Tetramethyl-1-((3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)methoxy)piperidine (**9**): 102 mg, 71% yield, white solid, mp 169–170 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, *J* = 8.4 Hz, 2H), 7.71–7.68 (m, 2H), 7.44–7.36 (m, 3H), 7.27 (d, *J* = 8.4 Hz, 2H), 4.31 (dd, *J* = 9.2, 3.6 Hz, 1H), 4.12 (dd, *J* = 9.6, 7.2 Hz, 1H), 4.00–3.92 (m, 1H), 3.21–3.06 (m, 2H), 2.38 (s, 3H), 1.51–1.45 (m,

1 5H), 1.32–1.31 (m, 1H), 1.23 (s, 6H), 1.08 (s, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 158.3, 144.1,
2
3 132.2, 130.9, 130.5, 129.5, 128.6, 128.5, 126.9, 59.9, 39.6, 37.4, 33.2, 33.0, 21.6, 20.1, 17.0; HRMS
4
5 (ESI): calcd for $\text{C}_{26}\text{H}_{35}\text{N}_3\text{O}_3\text{SNa}$ $[\text{M} + \text{Na}]^+$ 492.2300, found 492.2291.
6
7
8
9

10 ASSOCIATED CONTENT

11 12 13 14 Supporting Information

15
16 The Supporting Information is available free of charge on the ACS Publications website at DOI:

17
18 Copies of the ^1H NMR, ^{19}F NMR, $^{13}\text{C}\{^1\text{H}\}$ NMR and HRMS spectra of **5**, **6**, **7**, **9** and crystallography
19
20 of **5ac** (PDF).
21
22

23
24 Crystallographic data for **5ac**
25
26
27

28 29 AUTHOR INFORMATION

30 31 32 Corresponding Authors

33
34 *E-mail: huyl@nwnu.edu.cn.
35
36

37 ORCID

38
39 Yingpeng Su: 0000-0002-4396-4198
40
41

42 Yulai Hu: 0000-0002-9630-4150
43
44

45 Notes

46
47 The authors declare no competing financial interest.
48
49
50
51

52 ACKNOWLEDGMENTS

53
54
55 We are thankful for financial support from the National Natural Science Foundation of China
56
57 (Grant Nos. 21662030 and 21462037); Key Laboratory Polymer Materials of Gansu Province
58
59

(Northwest Normal University); Bioactive Product Engineering Research Center for Gansu Distinctive Plants; and State Key Laboratory of Applied Organic Chemistry, Lanzhou University.

REFERENCES

- (1) (a) Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; Izawa, K.; Liu, H. *Chem. Rev.* **2016**, *116*, 422. (b) Nenajdenko, V. G.; Muzalevskiy, V. M.; Shastin, A. V. *Chem. Rev.* **2015**, *115*, 973. (c) Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; Fustero, S.; Soloshonok, V. A.; Liu, H. *Chem. Rev.* **2014**, *114*, 2432. (d) Nie, J.; Guo, H.-C.; Cahard, D.; Ma, J.-A. *Chem. Rev.* **2011**, *111*, 455. (e) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. *Chem. Soc. Rev.* **2008**, *37*, 320. (f) Hagmann, W. K. *J. Med. Chem.* **2008**, *51*, 4359. (g) Müller, K.; Faeh, C.; Diederich, F. *Science* **2007**, *317*, 1881. (h) Caron, S.; Do, N. M.; Sieser, J. E.; Arpin, P.; Vazquez, E. *Org. Process. Res. Dev.* **2007**, *11*, 1015. (i) Corbett, J. W.; Ko, S. S.; Rodgers, J. D.; Gearhart, L. A.; Magnus, N. A.; Bacheler, L. T.; Diamond, S.; Jeffrey, S.; Klabe, R. M.; Cordova, B. C.; Garber, S.; Logue, K.; Trainor, G. L.; Anderson, P. S.; Erickson-Viitanen, S. K. *J. Med. Chem.* **2000**, *43*, 2019.
- (2) (a) Jeschke, P. *Pest Manag. Sci.* **2010**, *66*, 10. (b) Jeschke, P. *ChemBioChem* **2004**, *5*, 570. (c) Maienfisch, P.; Hall, R. G. *Chimia* **2004**, *58*, 93. (d) Fujiwara, T.; O'Hagan, D. *J. Fluorine Chem.* **2014**, *167*, 16.
- (3) (a) Vitale, A.; Bongiovanni, R.; Ameduri, B. *Chem. Rev.* **2015**, *115*, 8835. (b) Mishra, S.; Daniele, S. *Chem. Rev.* **2015**, *115*, 8379. (c) Berger, R.; Resnati, G.; Metrangolo, P.; Weber, E.; Hulliger, J. *Chem. Soc. Rev.* **2011**, *40*, 3496. (d) Meyer, F. *Prog. Polym. Sci.* **2015**, *47*, 70. (e) Zhang, L.; Sun, X.; Liu, Y.; Peng, Z.; Xuan, L. *Liq. Cryst.* **2012**, *39*, 983. (f) Schlosser, M. *Angew. Chem. Int. Ed.* **2006**, *45*, 5432.
- (4) For selected reviews, see: (a) Charpentier, J.; Früh, N.; Togni, A. *Chem. Rev.* **2015**, *115*, 650. (b)

1 Liu, X.; Xu, C.; Wang, M.; Liu, Q. *Chem. Rev.* **2015**, *115*, 683. (c) Merino, E.; Nevado, C. *Chem.*
2 *Soc. Rev.* **2014**, *43*, 6598. (d) Chu, L.; Qing, F.-L. *Acc. Chem. Res.* **2014**, *47*, 1513. (e) Liang, T.;
3 Neumann, C. N.; Ritter, T. *Angew. Chem. Int. Ed.* **2013**, *52*, 8214. (f) Furuya, T.; Kamlet, A. S.;
4 Ritter, T. *Nature* **2011**, *473*, 470.

5
6
7
8
9
10 (5) (a) Barata-Vallejo, S.; Lantaño, B.; Postigo, A. *Chem.-Eur. J.* **2014**, *20*, 16806. (b) Lonca, G. H.;
11 Ong, D. Y.; Tran, T. M. H.; Tejo, C.; Chiba, S.; Gagosz, F. *Angew. Chem. Int. Ed.* **2017**, *56*, 11440.
12 (c) Ide, T.; Masuda, S.; Kawato, Y.; Egami, H.; Hamashima, Y. *Org. Lett.* **2017**, *19*, 4452. (d)
13 Zhang, Y.; Guo, D.; Ye, S.; Liu, Z.; Zhu, G. *Org. Lett.* **2017**, *19*, 1302.

14
15
16
17
18
19
20 (6) (a) Zhang, C. *Org. Biomol. Chem.* **2014**, *12*, 6580. (b) Umemoto, T. *Chem. Rev.* **1996**, *96*, 1757.
21 (c) Xu, Y.; Wu, Z.; Jiang, J.; Ke, Z.; Zhu, C. *Angew. Chem. Int. Ed.* **2017**, *56*, 4545. (d)
22 Gietter-Burch, A. A. S.; Devannah, V.; Watson, D. A. *Org. Lett.* **2017**, *19*, 2957.

23
24
25
26
27 (7) (a) Prakash, G. K. S.; Yudin, A. K. *Chem. Rev.* **1997**, *97*, 757. (b) Dilman, A. D.; Levin, V. V.
28 *Eur. J. Org. Chem.* **2011**, 831. (c) Cho, E. J.; Senecal, T. D.; Kinzel, T.; Zhang, Y.; Watson, D. A.;
29 Buchwald, S. L. *Science* **2010**, *328*, 1679. (d) Wang, Q.; He, L.; Li, K. K.; Tsui, G. C. *Org. Lett.*
30 **2017**, *19*, 658.

31
32
33
34
35
36
37 (8) (a) Zhang, C. *Adv. Synth. Catal.* **2014**, *356*, 2895. (b) Jana, S.; Verma, A.; Kadu, R.; Kumar, S.
38 *Chem. Sci.* **2017**, *8*, 6633. (c) Fang, J.; Wang, Z.-K.; Wu, S.-W.; Shen, W.-G.; Ao, G.-Z.; Liu, F.
39 *Chem. Commun.* **2017**, 7638. (d) Li, J.; Zhang, X.; Xiang, H.; Tong, L.; Feng, F.; Xie, H.; Ding, J.;
40 Yang, C. *J. Org. Chem.* **2017**, *82*, 6795.

41
42
43
44
45
46
47 (9) (a) Wang, Y.-F.; Lonca, G. H.; Chiba, S. *Angew. Chem. Int. Ed.* **2014**, *53*, 1067. (b) Danoun, G.;
48 Bayarmagnai, B.; Grünberg, M. F.; Gooßen, L. J. *Angew. Chem. Int. Ed.* **2013**, *52*, 7972. (c) Wu, X.;
49 Chu, L.; Qing, F.-L. *Angew. Chem. Int. Ed.* **2013**, *52*, 2198. (d) Wang, X.; Xu, Y.; Mo, F.; Ji, G.;
50 Qiu, D.; Feng, J.; Ye, Y.; Zhang, S.; Zhang, Y.; Wang, J. *J. Am. Chem. Soc.* **2013**, *135*, 10330. (e)
51 Hafner, A.; Bräse, S. *Angew. Chem. Int. Ed.* **2012**, *51*, 3713. (f) Seo, S.; Taylor, J. B.; Greaney, M.

- 1 F. *Chem. Commun.* **2013**, 6385. (g) Wang, Q.; Dong, X.; Xiao, T.; Zhou, L. *Org. Lett.* **2013**, *15*,
2 4846. (h) Ye, Y.; Lee, S. H.; Sanford, M. S. *Org. Lett.* **2011**, *13*, 5464.
- 3
4
5 (10) (a) Pinto, G.; Rohrig, B. *J. Chem. Educ.* **2003**, *80*, 41. (b) Tilstam, U.; Weinmann, H. *Org.*
6
7 *Process Res. Dev.* **2002**, *6*, 384.
- 8
9
10 (11) (a) Combe, S. H.; Hosseini, A.; Parra, A.; Schreiner, P. R. *J. Org. Chem.* **2017**, *82*, 2407. (b)
11
12 Gaspa, S.; Porcheddu, A.; De Luca, L. *Org. Lett.* **2015**, *17*, 3666. (c) Jing, Y.; Daniliuc, C. G.;
13
14 Studer, A. *Org. Lett.* **2014**, *16*, 4932. (d) Gaspa, S.; Porcheddu, A.; De Luca, L. *Adv. Synth. Catal.*
15
16 **2016**, *358*, 154. (e) Zhao, N.; Xuan, S.; Fronczek, F. R.; Smith, K. M.; Vicente, M. G. H. *J. Org.*
17
18 *Chem.* **2015**, *80*, 8377. (f) Vo, T. T.; Zhang, J.; Parrish, D. A.; Twamley, B.; Shreeve, J. M. *J. Am.*
19
20 *Chem. Soc.* **2013**, *135*, 11787.
- 21
22
23 (12) Zhang, W.; Su, Y.; Wang, K.-H.; Wu, L.; Chang, B.; Shi, Y.; Huang, D.; Hu, Y. *Org. Lett.*
24
25 **2017**, *19*, 376.
- 26
27
28 (13) (a) Kashiwa, M.; Kuwata, Y.; Sonoda, M.; Tanimori, S. *Tetrahedron* **2016**, *72*, 304. (b)
29
30 Abdel-Halim, M.; Diesel, B.; Kiemer, A. K.; Abadi, A. H.; Hartmann, R. W.; Engel, M. *J. Med.*
31
32 *Chem.* **2014**, *57*, 6513. (c) Acker, T. M.; Khatri, A.; Vance, K. M.; Slabber, C.; Bacsa, J.; Snyder, J.
33
34 P.; Traynelis, S. F.; Liotta, D. C. *J. Med. Chem.* **2013**, *56*, 6434. (d) Silver, K. S.; Soderlund, D. M.
35
36 *Pestic. Biochem. Phys.* **2005**, *81*, 136. (e) Lee, D.-H.; Son, J. B.; Jung, S.; Song, J.; Ham, S. W.
37
38 *Tetrahedron Lett.* **2005**, *46*, 7721.
- 39
40
41 (14) (a) Reddy, M. V. R.; Billa, V. K.; Pallela, V. R.; Mallireddigari, M. R.; Boominathan, R.;
42
43 Gabriel, J. L.; Reddy, E. P. *Bioorg. Med. Chem.* **2008**, *16*, 3907. (b) Cunico, W.; Cechinel, C. A.;
44
45 Bonacorso, H. G.; Martins, M. A. P.; Zanatta, N.; de Souza, M. V. N.; Freitas, I. O.; Soares, R. P. P.;
46
47 Krettli, A. U. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 649. (c) Zhang, X.; Li, X.; Allan, G. F.; Sbriscia,
48
49 T.; Linton, O.; Lundeen, S. G.; Sui, Z. *J. Med. Chem.* **2007**, *50*, 3857. (d) Calvet, C.; Cuberes, R.;
50
51 Pérez-Maseda, C.; Frigola, J. *Electrophoresis* **2002**, *23*, 1702.
- 52
53
54
55
56
57
58
59
60

1 (15) (a) Qin, S.; Zheng, Y.; Zhang, F.-G.; Ma, J.-A. *Org. Lett.* **2017**, *19*, 3406. (b) Zhang, F.-G.;
2
3 Wei, Y.; Yi, Y.-P.; Nie, J.; Ma, J.-A. *Org. Lett.* **2014**, *16*, 3122. (c) Slobodyanyuk, E. Y.;
4
5 Artamonov, O. S.; Shishkin, O. V.; Mykhailiuk, P. K. *Eur. J. Org. Chem.* **2014**, 2487. (d) Someya,
6
7 C. I.; Inoue, S.; Irran, E.; Krackl, S.; Enthaler, S. *Eur. J. Inorg. Chem.* **2011**, 2691. (e) Yu, M.; Yang,
8
9 H.; Wu, K.; Ji, Y.; Ju, L.; Lu, X. *Bioorg. Med. Chem.* **2014**, *22*, 4109. (f) Wei, Q.; Chen, J.-R.; Hu,
10
11 X.-Q.; Yang, X.-C.; Lu, B.; Xiao, W.-J. *Org. Lett.* **2015**, *17*, 4464.
12
13
14

15 (16) (a) Hu, M.; He, Z.; Gao, B.; Li, L.; Ni, C.; Hu, J. *J. Am. Chem. Soc.* **2013**, *135*, 17302. (b) Hu,
16
17 M.; Ni, C.; Hu, J. *J. Am. Chem. Soc.* **2012**, *134*, 15257. (c) Liu, J.-B.; Chen, C.; Chu, L.; Chen,
18
19 Z.-H.; Xu, X.-H.; Qing, F.-L. *Angew. Chem. Int. Ed.* **2015**, *54*, 11839. (d) Liu, J.-B.; Xu, X.-H.;
20
21 Qing, F.-L. *Org. Lett.* **2015**, *17*, 5048. (e) Tomashenko, O. A.; Grushin, V. V. *Chem. Rev.* **2011**, *111*,
22
23 4475.
24
25
26

27 (17) (a) Duan, X.-Y.; Yang, X.-L.; Jia, P.-P.; Zhang, M.; Han, B. *Org. Lett.* **2015**, *17*, 6022. (b) Hu,
28
29 X.-Q.; Chen, J.-R.; Wei, Q.; Liu, F.-L.; Deng, Q.-H.; Beauchemin, A. M.; Xiao, W.-J. *Angew. Chem.*
30
31 *Int. Ed.* **2014**, *53*, 12163.
32
33
34

35 (18) (a) Morstein, J.; Hou, H.; Cheng, C.; Hartwig, J. F. *Angew. Chem. Int. Ed.* **2016**, *55*, 8054. (b)
36
37 Hu, M.; Ni, C.; Hu, J. *J. Am. Chem. Soc.* **2012**, *134*, 15257. (c) Tomashenko, O. A.; Escudero-Adán,
38
39 E. C.; Belmonte, M. M.; Grushin, V. V. *Angew. Chem. Int. Ed.* **2011**, *50*, 7655.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60